China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase II study assessing its polypeptide drug candidate RAY1225 in obese and overweight patients. This marks a significant step forward in the global development of this innovative therapy.
RAY1225: Dual-Activation GLP-1 Drug
RAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug with dual activation activity of the GLP-1 receptor and glucose-dependent insulin-promoting polypeptide (GIP) receptor. The drug is under development for use in blood sugar reduction, weight loss, and metabolic syndrome treatment. Previously, Part A of a Phase II clinical study in obese/overweight patients and type 2 diabetes patients in China met the primary endpoint, demonstrating the drug’s potential efficacy and safety.
Future Development and Clinical Trials
With the FDA’s approval, Zhongsheng Pharmaceutical is poised to advance the clinical development of RAY1225. The Phase II study in the US will provide further insights into the drug’s safety and efficacy in treating obesity and overweight conditions. This development underscores Zhongsheng’s commitment to advancing innovative therapies for metabolic disorders.-Fineline Info & Tech
